A statistically significant difference in NACC1 expression was demonstrated between the analyzed races in female tumors—that is, breast invasive carcinoma, ovarian serous cystadenocarcinoma, and uterine corpus endometrial carcinoma—as well as in kidney renal clear cell carcinoma and esophageal carcinoma. This evidence concerns the gene NACC1 and ovarian serous cystadenocarcinoma.